The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
Open accessAbstract
Background The epidermal growth factor receptor (EGFR) is a validated target in squamous cell carcinoma of the head and neck but in patients with recurrent or metastatic disease, EGFR targeting agents have displayed modest efficacy. Vascular endothelial growth factor (VEGF) mediated angiogenesis has been implicated as a mechanism of resistance to anti-EGFR therapy. This study combined an EGFR inhibitor, erlotinib, with an anti-VEGF antibody, bevacizumab. Methods This multi-institutional phase I/II study enrolled patients with recurrent or metastatic squamous cell carcinoma of the head and neck to receive erlotinib (150 mg daily) and bevacizumab in escalating dose cohorts. The primary objectives in the phase I and II portions, respectively, were to determine the maximum tolerated dose and dose-limiting toxicity of bevacizumab when administered with erlotinib and to determine the objective response rate and time to disease progression. Pre-treatment serum and tissues were collected and analyzed by Enzyme-Linked ImmunoSorbent Assay and immunofluorescence quantitative laser analysis, respectively. This study was registered with ClinicalTrials.gov, number NCT00055913. Findings The phase I portion enrolled 10 subjects in three successive cohorts without dose-limiting toxicity observed. An additional 46 subjects were enrolled at the phase II dose (bevacizumab 15 mg/kg every 3 weeks). The most common toxicities of any grade were rash and diarrhea (41 and 16 of 48 subjects, respectively). Three patients experienced serious bleeding events. The observed response rate was 15% with 4 complete responses (CR) allowing rejection of the null hypothesis. The median overall and progression-free survival (PFS) durations were 7.1 (95% Confidence Interval: 5.7 to 9.0) and 4.1 (95% Confidence Interval: 2.8 to 4.4) months, respectively. Higher ratios of phosphorylated over total VEGF receptor-2 and EGFR in pre-treatment biopsies were associated with CR (0.7043 vs. 0.3857, p=0.036 and 0.949 vs. 0.332, p=0.036, respectively) and tumor shrinkage (p=0.007 and p=0.008, respectively) in a subset of 11 subjects with available tissue. Interpretation The combination of erlotinib and bevacizumab is well tolerated in recurrent or metastatic squamous cell carcinoma of the head and neck. Some patients appear to derive a sustained benefit and complete responses were associated with expression of putative targets in pre-treatment tumor tissue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726
TIME-DEPENDENT COVARIATES IN THE COX PROPORTIONAL-HAZARDS REGRESSION MODEL
Fisher, L. D., & Lin, D. Y. (1999) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.20.1.145 · Cited by 1,054
Vermorken, J. B., Trigo, J., Hitt, R., Koralewski, P., Diaz-Rubio, E., Rolland, F., Knecht, R., Amellal, N., Schueler, A., & Baselga, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7447 · Cited by 1,009
Design and Analysis of Phase I Clinical Trials
Storer, B. E. (1989) · Biometrics · doi:10.2307/2531693 · Cited by 930
Soulieres, D., Senzer, N. N., Vokes, E. E., Hidalgo, M., Agarwala, S. S., & Siu, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.075 · Cited by 807
Self-citationEstimates of the world‐wide prevalence of cancer for 25 sites in the adult population
Pisani, P., Bray, F., & Parkin, D. M. (2002) · International Journal of Cancer · doi:10.1002/ijc.1571 · Cited by 730
Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Cohen, E. E. W., Rosen, F., Stadler, W. M., Recant, W., Stenson, K., Huo, D., & Vokes, E. E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.051 · Cited by 610
Self-citation
Cited by
Wilken, R., Veena, M. S., Wang, M. B., & Srivatsan, E. S. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-12 · Cited by 1,066
Lee, N. Y., Zhang, Q., Pfister, D. G., Kim, J., Garden, A. S., Mechalakos, J., Hu, K., Le, Q. T., Colevas, A. D., Glisson, B. S., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70303-5 · Cited by 359
Biomarkers to predict the clinical efficacy of bevacizumab in cancer
Jubb, A. M., & Harris, A. L. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70232-1 · Cited by 295
Targeted therapy for head and neck cancer: signaling pathways and clinical studies
Li, Q., Tie, Y., Alu, A., Ma, X., & Shi, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01297-0 · Cited by 253
Gyanchandani, R., Ortega Alves, M. V., Myers, J. N., & Kim, S. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0358 · Cited by 73
Metadata
- Authors
- Cohen, E. E., Davis, D. W., Karrison, T. G., Seiwert, T. Y., Wong, S. J., Nattam, S., Kozloff, M. F., Clark, J. I., Yan, D.-H., Liu, W., Pierce, C., Dancey, J. E., Stenson, K., Blair, E., Dekker, A., & Vokes, E. E.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2009-03
- Volume
- 10
- Issue
- 3
- Pages
- 247-257
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2104810134
- Cited by
- 273
- References
- 33
- FWCI
- 34.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. https://app.cochat.ai/papers/10.1016/s1470-2045(09)70002-6
- The paper
- Cohen, E. E., Davis, D. W., Karrison, T. G., Seiwert, T. Y., Wong, S. J., Nattam, S., Kozloff, M. F., Clark, J. I., Yan, D.-H., Liu, W., Pierce, C., Dancey, J. E., Stenson, K., Blair, E., Dekker, A., & Vokes, E. E. (2009). Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(09)70002-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.